TLDR Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
This study assessed the effectiveness of baricitinib, a JAK inhibitor, in treating 14 patients with severe alopecia areata. Over 3 to 12 months, 57% of patients experienced at least a 50% improvement in hair regrowth, with 21% achieving complete regrowth. Adverse events were mild. The study concludes that baricitinib is effective and well-tolerated for treating refractory alopecia areata, but larger trials are necessary to confirm these results.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
4 citations
,
September 2022 in “Dermatologic Therapy” Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
95 citations
,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.